• Heerspink HJL, et al. Sparsentan in patients with IgA nephropathy: A prespecified interim analysis from a randomised, double-blind, active-controlled clinical trial. Lancet 2023; 401:15841594. doi: 10.1016/S0140-6736(23)00569-X

    • PubMed
    • Search Google Scholar
    • Export Citation

Decreased Proteinuria with Sparsentan in IgA Nephropathy

Restricted access
Save